SMYD2 and gastric adenocarcinoma: SMYD2/3/5 expression was significantly increased in the TP53 mutation group of ESCA, LIHC, and STAD patients (Figures 3A–C), indicating that TP53 mutations may be involved in the regulation of mRNA expression of SMYD family members.